Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083061 | 0.78 | RAB9A (0.74) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL7945840 | 0.78 | RAB9A (0.70) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL1715458 | 0.77 | POLB (0.60) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL28317903 | 0.76 | RAB9A (0.67) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL17109793 | 0.75 | ALDH1A1 (0.88) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL28328243 | 0.75 | MEN1 (0.70) | NPC1ALOX5ALDH1A1MEN1KMT2A | |
| SCHEMBL8334964 | 0.75 | ALOX5 (0.70) | NPC1RAB9AALOX5ALDH1A1MAPT | |
| SCHEMBL7954413 | 0.73 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2APTGS2 | |
| SCHEMBL7875424 | 0.73 | ALOX5 (0.68) | NPC1RAB9AALOX5ALDH1A1MAPT | |
| SCHEMBL1708181 | 0.73 | ALOX5 (0.62) | NPC1RAB9AALOX5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | NPC1 2834/4885RAB9A 152/4885ALOX5 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.